Skip to main content
Midas Edge

BRAINSTORM CELL THERAPEUTICS INC.

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

BCLI$0.97+1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Interim Condensed Statements of Changes in Stockholders’ Equity (Deficit)

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY**(UNAUDITED)**

​​​​​​​​​​​​​
​​​​​​Additional​​​​​Total
​ · ​ · Common stock · ​ · paid-in · ​ · Treasury · ​ · Accumulated · ​ · stockholders’
​ · Number (**) · Amount · capital · stocks · deficit · deficit
Balance as of January 1, 20244,032,614​13​210,258​(116)​(215,013)​(4,858)
Stock-based compensation related to stock and options granted to directors and employees—​*​170​—​—​170
Issuance of shares in at-the-market (ATM) offering (Note 5)​530,532​*​2,539​—​—​2,539
Net loss—​—​—​—​(3,401)​(3,401)
Balance as of March 31, 2024​4,563,146​13​212,967​(116)​(218,414)​(5,550)
Stock-based compensation related to stock and options granted to directors and employees​111,721​*​194​—​—​194
Issuance of shares in at-the-market (ATM) offering (Note 5)​107,011​*​725​—​—​725
Issuance of shares for private placement (Note 5)​527,918​1​3,644​—​—​3,645
Net loss​—​—​—​—​(2,541)​(2,541)
Balance as of June 30, 2024​5,309,796​14​217,530​(116)​(220,955)​(3,527)
Stock-based compensation related to stock and options granted to directors and employees​—​*​178​—​—​178
Net loss​—​—​—​—​(2,708)​(2,708)
Balance as of September 30, 2024​5,309,796​14​217,708​(116)​(223,663)​(6,057)

*Represents an amount less than $1.

**Retroactively adjusted (See Note 5).

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) (UNAUDITED)

​​​​​​​​​​​​​
​​​​​​Additional​​​​​Total
​ · ​ · Common stock · ​ · paid-in · ​ · Treasury · ​ · Accumulated · ​ · stockholders’
​ · Number · Amount · capital · stocks · deficit · deficit
Balance as of January 1, 20256,141,762​14​218,974​(116)​(226,636)​(7,764)
Stock-based compensation related to stock and options granted to directors and employees—​*​717​—​—​717
Issuance of shares in at-the-market (ATM) offering (Note 5)​388,059​*​685​—​—​685
Exercise of warrants (Note 5)​1,381,383​1​1,768​—​—​1,769
Net loss​—​—​—​—​(2,864)​(2,864)
Balance as of March 31, 2025​7,911,204​15​222,144​(116)​(229,500)​(7,457)
Stock-based compensation related to stock and options granted to directors and employees​—​*​503​—​—​503
Issuance of shares in at-the-market (ATM) offering (Note 5)​1,927,655​1​3,349​—​—​3,350
Debt-for-Equity Swap​281,250​*​450**—​—​450
Net loss​—​—​—​—​(2,903)​(2,903)
Balance as of June 30, 2025​10,120,109​16​226,446​(116)​(232,403)​(6,057)
Stock-based compensation related to stock and options granted to directors and employees​658,666​*​157​—​—​157
Issuance of shares in at-the-market (ATM) offering (Note 5)​256,000​*​313​—​—​313
Net loss​—​—​—​—​(2,106)​(2,106)
Balance as of September 30, 2025​11,034,775​16​226,916​(116)​(234,509)​(7,693)
  • Represents an amount less than $1.

**During the reporting period, the Company settled outstanding accounts payable to a supplier in the amount of $450 through the issuance of 281,250 shares of common stock. This transaction was accounted for as a debt-for-equity swap.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.